GNRX

VanEck Vectors Generic Drugs ETF

Down$22.42
$-0.01
(-0.06%)
As of 7:43:33 PM EDT | 4/04/19  |  Market Closed

GNRX Trading Data

Open

$22.17

Low Price

$22.17

High Price

$22.42

Previous Last Price

$22.43

Bid Size

$ X

Ask Size

$ X

GNRX Portfolio Data

AUM

$3,357,800

Shares

150

PE Ratio

28.27

Price / Book Ratio

2.64

Expense Ratio

0.55

Net Asset Value

$22.39

Volume

Volume

3,300

Avg. Volume (YDT)

1,309

Dollar Volume

$0

Weekly Avg. Volume

1,200

Monthly Avg. Volume

755

Quarterly Avg. Volume

1,420

GNRX Fund Description

The VanEck Vectors Generic Drugs ETF seeks to replicate as closely as possible, before fees and expenses, the price and yield performance of the Indxx Global Generics and New Pharma Index, which is intended to track the overall performance of companies that derive a significant proportion of their revenues or that have the potential to derive a significant proportion of their revenues from the generic drug industry, or that have a primary business focus on the generic drug industry. Expenses for GNRX are capped contractually at 0.55% until at least February 1, 2018. Cap excludes certain expenses, such as interest.

GNRX Chart

GNRX Summary

Fund Family

Van Eck Associates

Tracks This Index

VanEck Vectors Generic Drugs ETF

Inception Date

2016-01-12

Asset Class

Equity

Asset Class Size

International

GNRX Classification

Region (General)

Global

Region (Specific)

Sector

Equity Index

Leveraged Family

GNRX Technicals

Alpha

-13.01

Beta

1.12

Leverage

Long

Standard Deviation

1.63

GNRX Dividends

Dividend Date

2018-12-20

Latest Dividend

0.006

Annual Dividend

0.01

Annual Dividend Rate

0.01

Annual Dividend Yield

0.03

GNRX Performance

YTD Return

8.29%

1 Year Return

-6.95%

3 Year Return

-6.79%

5 Year Return

0%

10 Year Return

-8.21%

GNRX Related Articles

© 2019 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions.

Fundamental company data provided by Morningstar and Zacks Investment Research. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.